Liquid biopsies: envisioning a future when tissue is avoidable in lung cancer treatment decision-making

During the last years we have witnessed a revolution in the genomic profiling and molecular characterization of lung cancer. Epidermal growth factor receptor (EGFR) is, among other signaling pathways such as ALK, BRAF, MET or ROS, one of the key oncogenes with potential for targeted-inhibition. Therefore, a complete basal genomic profiling is now recommended in the clinical diagnostic workup to select the optimal personalized therapy for each lung cancer patient (1).